Latest news with #Xiidra
Health Line
11-08-2025
- Health
- Health Line
Medicare Coverage of Xiidra
Medicare may cover Xiidra (lifitegrast ophthalmic solution) if you have a plan with prescription drug coverage, such as a Part D plan or a Medicare Advantage (Part C) plan. Xiidra is a brand-name drug that doctors may prescribe to treat the symptoms of dry eye disease. Medicare and Xiidra Xiidra belongs to a group of drugs called a lymphocyte function-associated antigen-1 (LFA-1) antagonist. The drug is approved by the Food and Drug Administration (FDA) to treat the signs and symptoms of dry eye disease. To receive coverage for Xiidra, you need to have a Medicare prescription drug plan. If you have Original Medicare (parts A and B), you can enroll in a stand-alone Part D plan to cover your medications. If you have a Medicare Advantage plan, you likely have prescription drug coverage as part of your plan. However, not all Medicare Advantage plans include drug benefits. Private insurance companies offer Medicare drug plans, and their lists of covered drugs differ. Your plan will cover Xiidra if it's included in the plan's formulary. More than half of Medicare drug plans cover Xiidra. Review your plan's documentation or contact a representative to learn whether it covers Xiidra. If it does not, it may cover an alternative medication for dry eye disease. The Centers for Medicare & Medicaid Services (CMS) offers a coverage finder tool to allow users to find plans in their area that include coverage for Xiidra. Xiidra cost with Medicare The amount you pay for Xiidra will depend on a few factors. These include your location, your plan, and the drug's tier. Medicare prescription drug plans group covered drugs into cost tiers. Xiidra is typically a higher tier drug, with no generic version. The amount you pay for Xiidra will also depend on what stage of coverage you are in. In 2025, most Part D plans have three stages of coverage. Beneficiaries will have different out-of-pocket expenses depending on the stage: Deductible stage: If your plan has a deductible, you'll pay the full cost of the medication until you reach your deductible amount. In 2025, the maximum deductible amount for a Part D plan is $590. Initial coverage stage: After meeting your deductible, you'll pay a 25% coinsurance on the cost of covered medications until your out-of-pocket costs reach $2,000. Catastrophic stage: Once you've spent $2,000 in a calendar year, you'll pay no more for covered medications. If you qualify for cost assistance through the Extra Help program, your costs will be lower.
Yahoo
23-06-2025
- Business
- Yahoo
Barclays Cut Bausch & Lomb Target to $16, Keeping Rating Neutral in Early June
Barclays lowered its price target on Bausch & Lomb (NYSE: BLCO) from $19 to $16 on June 6, maintaining an Equalweight rating. The revision reflects a more cautious outlook on the company's near-term financial performance. The firm trimmed its next twelve-month EBITDA forecast to $996 million, down from $1.04 billion. As a result, the valuation multiple used in their model was reduced to 10.5x EV/EBITDA, just above the current trading level but below the stock's post-spin average of 11x. A medical professional wearing an eye mask, demonstrating the effectiveness of Bausch Health's ophthalmic solutions. Barclays also adjusted its sales and earnings projections. Sales estimates were shaved by less than 1% annually starting in 2025, in line with company guidance. The changes are driven in part by the expected impact of the Inflation Reduction Act and formulary shifts affecting Xiidra. EPS estimates saw a steeper drop, down around 12% for 2025, when guidance changes and the fallout from the enVista recall are factored in. For 2026 and beyond, earnings projections have been lowered by 13–14% annually. We previously shared a . While we acknowledge the potential of BLCO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
